

Author Index Volume 24 (2015/2016)

The issue number is given in front of the pagination

- Arsang-Jang, S., see Hamedani, S.Y. (3,4) 59–64
Arsang-Jang, S., see Nazdik, M.K. (3,4) 65–70
Azimi, T., see Eftekharian, M.M. (3,4) 85–90
- Barabas, A.Z., C.D. Cole, R.M. Graeff, T. Morcol and R. Lafreniere, A novel modified vaccination technique produces IgG antibodies that cause complement-mediated lysis of multiple myeloma cells carrying CD38 antigen (3,4) 45–51
Barabas, A.Z., C.D. Cole, R.M. Graeff, Z.B. Kovacs and R. Lafreniere, Suppression of tumor growth by a heterologous antibody directed against multiple myeloma dominant CD38 antigen in SCID mice injected with multiple myeloma cells (3,4) 53–57
Basyreva, L.Y., I.B. Brodsky, A.A. Gusev, O.N. Zhaparova, E.V. Mikhalchik, S.A. Gusev, D.B.-A. Shor, S. Dahan, M. Blank and Y. Shoenfeld, The effect of Intravenous Immunoglobulin (IVIg) on *ex vivo* activation of human leukocytes (3,4) 39–44
Bazaz, M., see Esmati, L. (3,4) 77–83
Blank, M., see Basyreva, L.Y. (3,4) 39–44
Borzooei, S., see Eftekharian, M.M. (1,2) 25–31
Brodsky, I.B., see Basyreva, L.Y. (3,4) 39–44
Buerckert, J.-P., see Dubois, A.R.S.X. (1,2) 1–15
- Cole, C.D., see Barabas, A.Z. (3,4) 45–51
Cole, C.D., see Barabas, A.Z. (3,4) 53–57
- Dahan, S., see Basyreva, L.Y. (3,4) 39–44
Dubois, A.R.S.X., J.-P. Buerckert, R. Sinner, W.J. Faison, A.M. Molitor and C.P. Muller, High-resolution analysis of the B cell repertoire before and after polyethylene glycol fusion reveals preferential fusion of rare antigen-specific B cells (1,2) 1–15
- Eftekharian, M.M., A. Sayad, M.D. Omrani, M.S. Ghannad, R. Noroozi, M. Mazdeh, R. Mirfakhraie, A. Movafagh, G. Roshanaei, T. Azimi, H. Inoko and M. Taheri, Single nucleotide polymorphisms in the *FOXP3* gene are associated with increased risk of relapsing-remitting multiple sclerosis (3,4) 85–90
Eftekharian, M.M., J. Karimi, M. Safe, A. Sadeghian, S. Borzooei and E. Siahpoushi, Investigation of the correlation between some immune system and biochemical indicators in patients with type 2 diabetes (1,2) 25–31
Eftekharian, M.M., M.S. Ghannad, M. Taheri, G. Roshanaei, M. Mazdeh, M. Musavi and M.B. Hormoz, Frequency of viral infections and environmental factors in multiple sclerosis (1,2) 17–23
Eftekharian, M.M., see Nemati, S. (1,2) 33–38
Esmati, L., J.F. Mehrabadi, M. Bazaz, H.R. Nejad, Construction of human anti-tetanus single-chain variable fragment applying SYMPLEX technology (3,4) 77–83
- Faison, W.J., see Dubois, A.R.S.X. (1,2) 1–15
- Ghannad, M.S., see Eftekharian, M.M. (1,2) 17–23
Ghannad, M.S., see Eftekharian, M.M. (3,4) 85–90
Graeff, R.M., see Barabas, A.Z. (3,4) 53–57
Gusev, A.A., see Basyreva, L.Y. (3,4) 39–44
Gusev, S.A., see Basyreva, L.Y. (3,4) 39–44
- Hamedani, S.Y., M. Taheri, E. Sajjadi, M.D. Omrani, M. Mazdeh, S. Arsang-Jang, A.S.T. Panah and A. Sayad, Up regulation of MMP9 gene expression in female patients with multiple sclerosis (3,4) 59–64
Hormoz, M.B., see Eftekharian, M.M. (1,2) 17–23

- Inoko, H., see Eftekharian, M.M. (3,4) 85–90
 Inoko, H., see Nazdik, M.K. (3,4) 65–70
- Karimi, J., see Eftekharian, M.M. (1,2) 25–31
 Kohan, L., see Rezaie, Z. (3,4) 71–76
 Koochpar, Z.K., see Nazdik, M.K. (3,4) 65–70
 Kovacs, Z.B., see Barabas, A.Z. (3,4) 53–57
- Lafreniere, R., see Barabas, A.Z. (3,4) 45–51
 Lafreniere, R., see Barabas, A.Z. (3,4) 53–57
- Mazdeh, M., see Eftekharian, M.M. (1,2) 17–23
 Mazdeh, M., see Eftekharian, M.M. (3,4) 85–90
 Mazdeh, M., see Hamedani, S.Y. (3,4) 59–64
 Mehrabadi, J.F., see Esmati, L. (3,4) 77–83
 Mikhalchik, E.V., see Basyreva, L.Y. (3,4) 39–44
 Mirfakhraie, R., see Eftekharian, M.M. (3,4) 85–90
 Mirfakhraie, R., see Nemati, S. (1,2) 33–38
 Molitor, A.M., see Dubois, A.R.S.X. (1,2) 1–15
 Morcol, T., see Barabas, A.Z. (3,4) 45–51
 Movafagh, A., see Eftekharian, M.M. (3,4) 85–90
 Movafagh, A., see Nemati, S. (1,2) 33–38
 Muller, C.P., see Dubois, A.R.S.X. (1,2) 1–15
 Musavi, M., see Eftekharian, M.M. (1,2) 17–23
- Nazdik, M.K., M. Taheri, E. Sajjadi, S. Arsang-Jang, Z.K. Koochpar, H. Inoko and A. Sayad, Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients (3,4) 65–70
 Nejad, H.R., see Esmati, L. (3,4) 77–83
 Nemati, S., M. Taheri, A. Movafagh, M. Saberi, R. Mirfakhraie, M.M. Eftekharian, A. Rezagholizadeh and A. Sayad, TRAIL gene expression analysis in multiple sclerosis patients (1,2) 33–38
 Noroozi, R., see Eftekharian, M.M. (3,4) 85–90
- Omrani, M.D., see Eftekharian, M.M. (3,4) 85–90
- Omrani, M.D., see Hamedani, S.Y. (3,4) 59–64
- Panah, A.S.T., see Hamedani, S.Y. (3,4) 59–64
- Rezagholizadeh, A., see Nemati, S. (1,2) 33–38
 Rezaie, Z., M. Taheri, L. Kohan and A. Sayad, Down-regulation of CYP27B1 gene expression in Iranian patients with Relapsing-Remitting multiple sclerosis (3,4) 71–76
 RGraeff, R.M., see Barabas, A.Z. (3,4) 45–51
 Roshanaei, G., see Eftekharian, M.M. (1,2) 17–23
 Roshanaei, G., see Eftekharian, M.M. (3,4) 85–90
- Saberi, M., see Nemati, S. (1,2) 33–38
 Sadeghian, A., see Eftekharian, M.M. (1,2) 25–31
 Safe, M., see Eftekharian, M.M. (1,2) 25–31
 Sajjadi, E., see Hamedani, S.Y. (3,4) 59–64
 Sajjadi, E., see Nazdik, M.K. (3,4) 65–70
 Sayad, A., see Eftekharian, M.M. (3,4) 85–90
 Sayad, A., see Hamedani, S.Y. (3,4) 59–64
 Sayad, A., see Nazdik, M.K. (3,4) 65–70
 Sayad, A., see Nemati, S. (1,2) 33–38
 Sayad, A., see Rezaie, Z. (3,4) 71–76
 Shoenfeld, Y., see Basyreva, L.Y. (3,4) 39–44
 Shor, D.B.-A., see Basyreva, L.Y. (3,4) 39–44
 Siahpoushi, E., see Eftekharian, M.M. (1,2) 25–31
 Sinner, R., see Dubois, A.R.S.X. (1,2) 1–15
- Taheri, M., see Eftekharian, M.M. (1,2) 17–23
 Taheri, M., see Eftekharian, M.M. (3,4) 85–90
 Taheri, M., see Hamedani, S.Y. (3,4) 59–64
 Taheri, M., see Nazdik, M.K. (3,4) 65–70
 Taheri, M., see Nemati, S. (1,2) 33–38
 Taheri, M., see Rezaie, Z. (3,4) 71–76
- Zhapparova, O.N., see Basyreva, L.Y. (3,4) 39–44